LING YUI (00784) change of controlling shareholder, received approximately 34.0% discount for full acquisition offer, resumes trading on April 15th.

LING YUI (00784) and the offeror HAPBIOTECH INVESTMENT HOLDING LIMITED jointly announced that on April 9, 2026, the offeror has completed the purchase of approximately 560 million shares, equivalent to 70.02% of the total issued share capital of the company as of the date of this joint announcement. The price is approximately HK$133 million (equivalent to HK$0.2375 per share). Following the completion and as of the date of this joint announcement, the offeror and its concerted parties collectively hold approximately 560 million shares, representing 70.02% of the issued shares. Pursuant to Rule 26.1 of the Takeover Code, the offeror is required to make a mandatory unconditional cash offer to acquire all the shares of the company's issued share capital (excluding shares already owned or agreed to be acquired by the offeror and its concerted parties). The financial advisor Hongri Capital (acting on behalf of the offeror) will make the offer based on the following terms, offering HK$0.2375 in cash per share, representing a discount of approximately 34.0% compared to the closing market price of HK$0.360 per share on the last trading day on the Stock Exchange. Moreover, the Board of Directors proposes to change the English name of the company from "Ling Yui Holdings Limited" to "AiLife International Group Limited," and to change the Chinese name from "LING YUI" to "." The company has applied for the resumption of trading of its shares on the Stock Exchange starting from 9:00 AM on April 15, 2026. As of the date of this joint announcement, all of the offeror's issued share capital is beneficially owned by Haplos Realities. Haplos Group is a genetic testing solutions provider, mainly focusing on the application of molecular diagnostic technology for precision medicine in China.